Pharmacological inhibition of TSP-1 decreases glioblastoma cell proliferation and network synchrony within the tumour microenvironment, highlighting a potential therapeutic strategy to be assessed in future clinical studies. This evidence concerns the gene THBS1 and glioblastoma.